Revenue
Q1.25
Q2.25
Q1.26
Q2.26
Atrium Therapeutics, Inc. (RNA)
Price—Loading quote
Net income
Q1.25
Q2.25
Q1.26
Q2.26
Free cash flow
Q1.25
Q2.25
Q1.26
Q2.26
Total cash / debt
CashTotal debt
Q1.25
Q1.26
Q2.26
Financial statements
| Q2.26 | Q1.26 | Q2.25 | Q1.25 | |
|---|---|---|---|---|
| Revenue | $3.0M | $19.6M | $3.8M | $1.6M |
| Research & development | $15.3M | $16.7M | $13.3M | $6.9M |
| Operating expenses | $25.6M | $36.9M | $16.7M | $9.0M |
| Operating income | −$22.6M | −$17.3M | −$12.9M | −$7.5M |
| Net income | −$20.2M | −$16.6M | −$12.9M | −$7.4M |
| Basic EPSper diluted share | -$1.18 | -$0.97 | -$0.75 | -$0.44 |
| Diluted EPSper diluted share | -$1.18 | -$0.97 | -$0.75 | -$0.44 |